Investor Presentaiton
Novo Nordisk Annual Report 2023
Net sales - Business segments and geographical areas
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information
Total International Operations
Total North America Operations
Total Novo Nordisk
net sales
Total IO
EMEA
China
Rest of World
2023
2022
2021
2023
2022
2021
2023
2022
2021
2023
2022
2021
2023
Total NAO
2022
US
2021
2023
2022
2021
2023
2022
2021
DKK million
Diabetes and Obesity care segment:
Rybelsus®
7,389
OzempicⓇ
26,378
VictozaⓇ
4,850
3,155
17,369
5,672
524
4,232
8,856 14,327
1,714
289
131
63
3,026
10,417
6,393
4,821
2,196
303
7,230
Total GLP-1
38,617 26,196 16,106
6,726 2,166
20,725
2,724
3,527
1,256
1,478
1,544
1,428
1,378
4,756
1,470
14,855 10,209
6,208
3,737
1,847
11,684
7,604
Long-acting insulin
11,339
11,403
11,074
7,103
7,157
6,729
1,649
1,636
2,080
2,587
2,610
2,265
235 11,361 8,144 4,314 11,060 8,011 4,243 18,750 11,299
2,160 69,340 42,381 24,849 63,010 38,750 23,168 95,718 59,750
1,655 3,814 6,650 8,328 3,613
6,406
8,031 8,664 12,322
4,050 84,515 57,175 37,491 77,683 53,167 35,442 123,132 83,371
3,566 5,338 6,990 2,931 4,685
6,412 14,905 16,741
4,838
33,705
15,054
53,597
18,064
⚫of which TresibaⓇ
5,864
6,092
5,486
3,435
3,485
2,979
848
1,050
1,095
1,581
1,557
1,412
1,888
3,261
4,243
1,333
2,723
3,793
7,752
9,353
9,729
of which XultophyⓇ
2,887
2,400
2,135
1,831
1,716
1,693
409
45
3
647
639
439
332
409
522
325
399
512
3,219
2,809
2,657
of which Levemir®
2,588
2,911
3,453
1,837
1,956
2,057
392
541
982
359
414
414
1,346
1,668
2,225
1,273
1,563
2,107
3,934
4,579
5,678
Premix insulin
9,342 10,023 10,512
2,570
2,622
2,879
4,441
4,912
5,224
2,331
2,489
2,409
232
539
691
216
517
665
9,574 10,562
11,203
of which Ryzodeg
3,730
2,889
1,711
587
495
392
1,965
1,218
283
1,178
1,176
1,036
3,730
2,889
1,711
⚫ of which NovoMix®
5,612
7,134
8,801
1,983
2,127
2,487
2,476
3,694
4,941
1,153
1,313
1,373
232
539
691
216
517
665
5,844
7,673
9,492
Fast-acting insulin
10,415
10,826 10,903
6,695
6,456
6,454
1,545
1,942
2,288
2,175
2,428
2,161
5,534
6,637
6,784
5,265
6,247
⚫of which Fiasp
1,512
1,354
1,106
1,266
1,138
965
246
216
141
661
649
642
618
606
6,357
605
of which NovoRapidⓇ
8,903
9,472
9,797
5,429
5,318
5,489
1,545
1,942
2,288
1,929
2,212
2,020 4,873
5,988
6,142
4,647
Human insulin
6,134
6,508
7,453
1,919
1,983
2,152
1,213
1,812
2,692
3,002
2,713
2,609
1,460
1,678
1,599
1,406
Total insulin
37,230
38,760 39,942 18,287
Other Diabetes care
1,987
2,428
Total Diabetes care
77,834
67,384
2,644
58,692
661
18,218
717
18,214
713
39,673
33,790
29,136
15,948
8,848 10,302
892 1,181
15,220
12,284
1,432
15,563
10,095
10,240
434
530
10,792
325
14,192
797
22,213
18,374
WegovyⓇ
1,913
54
1,913
54
SaxendaⓇ
6,402
5,832
3,117
3,780
3,561
Total Obesity care
8,315
5,886
3,117
5,693
3,615
Diabetes and Obesity care total
86,149
73,270 61,809
45,366
37,405
1,809
1,809
30,945
146
146
133
133
61
61
16,094
15,353
15,624
2,476
2,476
24,689
2,138
2,138
20,512
9,444
9,818
499
267
13,993 95,632 72,164 54,505 87,768 66,881
29,430 6,134 1,386 29,430 6,134
1,247
3,887
4,844 3,897
3,306
4,368
1,247 33,317 10,978 5,283 32,736 10,502
15,240 128,949 83,142 59,788 120,504 77,383
16,064
950
660
806
2,003
5,641 5,752 13,776 15,460
1,605 1,515 7,594 8,186
13,054 14,949 48,022 52,952
2,312
51,197 173,466
1,386 31,343
3,526 10,289 10,676
4,912 41,632 16,864
56,109 215,098 156,412
15,949 17,463
2,173
17,687
1,748
3,225
139,548
6,188
15,939
9,052
56,006
3,594
113,197
1,386
7,014
8,400
121,597
Rare disease segment:
Rare blood disorders
6,432
6,671
5,784
4,021
3,795
3,712
372
604
222
2,039
2,272
1,850
5,344
5,035
4,433
5,070
of which Haemophilia A
1,939
1,769
1,625
1,271
1,137
1,162
223
81
24
445
551
439
483
569
487
468
4,710
543
4,170 11,776 11,706
10,217
460
2,422
2,338
2,112
⚫of which Haemophilia B
584
479
400
377
294
268
13
13
4
194
172
128
477
280
237
336
152
102
1,061
759
637
⚫ of which NovoSeven®
3,789
4,335
3,673
2,285
2,311
2,225
136
510
194
1,368
1,514
1,254
4,169
3,973
3,548
4,065
3,811
3,461
7,958
8,308
7,221
Rare endocrine disorders
2,045
4,904
4,880
699
2,232
2,212
216
246
167
1,130
2,426
2,501
1,791
2,234
2,423
1,757
2,205
2,400
3,836
7,138
7,303
Other Rare disease
Rare disease total
1,006
1,002
1,064
781
804
837
5
6
6
220
192
221
545
696
619
203
358
330
1,551
1,698
1,683
9,483 12,577 11,728
5,501
Total sales by geographical area
95,632 85,847 73,537 50,867
Total sales growth as reported
11.4%
16.7% 11.7% 15.0%
6,831
44,236
17.3%
6,761
37,706 16,687
9.9% 2.9%
593
856
16,209
1.2%
395 3,389 4,890
16,019 28,078 25,402
13.7% 10.5% 28.2%
4,572 7,680
19,812 136,629
13.5% 50.0%
7,965
91,107
35.4%
7,475 7,030 7,273
67,263 127,534 84,656
10.1% 50.6% 34.4%
6,900 17,163 20,542
63,009 232,261 176,954 140,800
9.0% 31.3% 25.7%
19,203
10.9%
57View entire presentation